An open label study of the effects of rituximab in neuromyelitis optica
Top Cited Papers
- 12 April 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 64 (7) , 1270-1272
- https://doi.org/10.1212/01.wnl.0000159399.81861.d5
Abstract
Eight patients with worsening neuromyelitis optica were treated with rituximab to achieve B cell depletion. Treatment was well tolerated. Six of eight patients were relapse free and median attack rate declined from 2.6 attacks/patient/year to 0 attacks/patient/year (p = 0.0078). Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013).Keywords
This publication has 7 references indexed in Scilit:
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisPublished by Elsevier ,2004
- A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaBrain, 2002
- Plasma exchange for severe attacks of CNS demyelination: Predictors of responseNeurology, 2002
- Neuromyelitis OpticaSeminars in Neurology, 2002
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999
- Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprineNeurology, 1998
- Rating neurologic impairment in multiple sclerosisNeurology, 1983